Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Comment by Smokey1958on Apr 22, 2021 5:08pm
182 Views
Post# 33052085

RE:Ducks in a row!

RE:Ducks in a row!

I think the numbers are already there, Martin. From the NRs on the following dates....

December 6 Sensitivity 80% Specificity 90%+
January 18   Sensitivity 86% Specificity 100%
March 18      Sensitivity 100% Specificity 100% (locked test)
April 13         Initial Brazil studies confirm THRM lab testing
April 19 McWilliams wants to see 86% Specificity and 100% Sensitivity on expanded Brazil testing

No one has come out to say anything but it seems like these numbers may be backwards for April 19. Regardless AcuVid appears to have already met the "numbers" in the lab and in a small scale sample in situ in Brazil. The larger scale testing involving more individuals carrying the variant increases the sample size. Based on the NR today, if there was any necessary optimizing (tweaking) of the device that's already been taken care of. Testing now is just about solidifying the evidence ....to satisfy the conditions of sale and to prepare for EUA approval by the FDA ....and an application for review by HC.
 

martindale wrote: Looks like we are hitting our marks so far.. more specificity in the % numbers would be nice but they will update that soon I expect.. a little more tweaking may be required or maybe just more proving up the test..Sufficeto say today’s news release was very good.. having some partners get our manufacturing set up hints at more orders on the way soon.. also expecting an update regarding HC and the FDA in the next two weeks if not sooner... GLTA That Deserve It.! JM2CW... 

 

<< Previous
Bullboard Posts
Next >>